TF and metabolic dysfunction-associated steatotic liver disease: These results indicate that treatment with the R-Tf-D-LP4 peptide led to a reduction in NAFLD symptoms and reverted the diabetic phenotype of the model mice to close to that of the chow diet-fed mice.